medigraphic.com

2008, Number 6

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2008; 46 (6)

Vaccine Against Human Papilloma Virus

Juárez-Albarrán AC, Juárez-Gámez CA

Language: Spanish
References: 19
Page: 631-637
PDF size: 174.64 Kb.


ABSTRACT

Genital human papilloma virus infection (HPV) is the most common sexually transmitted infection worldwide, it is the cause of genital warts, and it is related with cervical cancer, the second most common cause of death from cancer in women in America, and the first in underdeveloped countries, and it is related with penis and prostate cancer in males also, and with anal cancer in both genders. This review examines the most important actual facts about HPV infection, and the new prophylactic vaccines. Two versions of the vaccine had been developed, both target HPV 16 and HPV 18, which involve approximately 70% of cervical cancer. One of them also targets HPV 6 and HPV 11, which account for approximately 90% of external genital warts. Both vaccines have an excellent safety profile, are highly immunogenic, and have atributed complete type specific protection against persistent infection and associated lesions in fully vaccinated girls and young women. The role of men as carriers of HPV as well as vectors for transmission is well documented. Several clinical trials are currently under way to determine the efficacy of vaccinating men. Reducing the cost of vaccination would be a priority for the developing world in order to get a broad target in poor countries.


REFERENCES

  1. Kaplan N, Dollin J. Cervical cancer awareness and HPV prevention in Canada. Can Fam Phys 2007. Disponible en http://www.cfpc.ca

  2. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest 2006;116(5):1167-1173.

  3. Food and Drugs Administration. Licences new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Disponible en http://fda.gov.bbs/topics/News/2006/New01385.html

  4. Frazer IH, Cox JT, Mayeaux EJ, Franco E, Moscicki AE, Palefsky JM, Ferris D, Ferenczy AS, Villa LL. Advances in prevention of cervical cancer and other human papillomavirus related diseases. Consensus Statement. Discussion Held in 2006, Vancouver, British Columbia. Crochane Review.

  5. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Disponible en http://www.infection.thelancet.com

  6. A human papillomavirus vaccine. (Medical Letter). Obst Gynecol 2007;109(1):191.

  7. Kodner CM, Nasraty S. Management of Genital Warts. Am Fam Physicians 2004;70:2335-2345.

  8. Armstrong C. Practice guidelines. ACIP Releases recommendations on quadrivalent human papillomavirus vaccine. Disponible en http://www. aafp.org/afp/20070501/practice.html

  9. Steinbrook R. the potential of human papillomavirus vaccines (perspective). N Engl J Med 2006; 354(11):1109-1112.

  10. Centers for Disease Control and Prevention. Condiloma acuminatum. CDC Sexually transmitted diseases guidelines 2006 on HPV infection and genital warts. Disponible en http://www.cdc.gov/STD/treatment/2006/genital-warts.htm

  11. Boon ME, Schneider A, Hogewoning C, Kwal TTH, Bolhius P, Kok PL. Penile studies in heterosexual partners. Peniscopy, citology, histology and inmunocytochemistry. Cancer 1988;61:1652-1659.

  12. Secretaría de Salud de México. Morbilidad 2005. Disponible en http://www.dgep.salud.gob.mx

  13. Jastreboff AM, Cymet T. Role of the human papilloma virus in the development of cervical intraepithelial neoplasia and malignancy. Posgrad Med J 2002; 78:225-228.

  14. Tirado GLL, Mohar BA, López CA, Franco MF, Borguez G. Factores de riesgo de cáncer cervicouterino invasor en mujeres mexicanas. Salud Publica Mex 2005;47(5):343-350.

  15. Lazcano PE, Herrero R, Muñoz N, Hernández AM, Salieron J, Leyva A, Meijer CLIM, Walboomers JMM. High Prevalence of human papillomavirus infection in mexican males. Comparative study of penile-urethral swabs and urine samples. Sex Transm Diss 2001;28(5):277-280.

  16. Blecker MCG, Hogewoning CJA, Van den Brule AJC, Voorhorst FJ, Van Andel RE, Risse EKJ, et al. Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. J Am Acad Dermatol 2002;47 (3):351-357.

  17. Hernández HDM, García CA, Guido JMC, González SJL, Cruz TF, Apresa GT, et al. Virus del papiloma humano de alto riesgo (VPH-AR) y neoplasia intraepitelial cervical (NIC) en mujeres de dos hospitales de la Ciudad de Mexico. Rev Invest Clin 2002;54(4)299-306.

  18. Ressinger K, Block SL, Lazcano PE, Samakoses R, Esser MT, Esrick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 5, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. Pediatric Infect Dis J 2007;26(3):201-209.

  19. Centers for Disease Control and Prevention’s Advisory Committee Recommends Human Papillomavirus. Virus vaccination. Disponible en http://www.Dynamic Medical.com




2020     |     www.medigraphic.com